登录 | 注册    关注公众号  
微信公众号
搜索
 >  Kits>TARC/CCL17 >CEA-C029

ClinMax™ Human TARC/CCL17 ELISA Kit

For research use only.

产品概述(Product Details)

ClinMax™ Human TARC/CCL17 ELISA Kit is a ready-to-use immunoassay kit, specifically designed to quantitate natural and recombinant human TARC/CCL17 that is present in biological samples, such as human serum, plasma, and cell culture supernatants. Our ClinMax™ ELISA Kit provides several benefits:

  1. Standards to calibrate with NIBSC/WHO standards for comparable results.
  2. Fully validation in biologic samples for detection range, sensitivity, inter- and intra-plate CV, recovery, dilution linearity, specificity, and matrix effects to ensure reliable results according to ICH M10 guideline.
  3. High-quality antibody pairs and protein standards, along with rigorous quality control, to guarantee consistent results across different batches.
  4. Simplified and straightforward protocols and ready-to-use reagents to save assay time.

应用说明(Application)

The kit is developed for quantitative detection of natural and recombinant human TARC/CCL17 in serum, plasma and cell culture supernatants. It is for research use only.

It is for research use only.

流程图(Workflow)

TARC/CCL17 Workflow

关键信息(Key Features)

AnalyteCCL17
Assay TypeSandwich-ELISA
ReactivityHuman
Sensitivity3.0 pg/mL
Range31.25pg/mL-2000 pg/mL
Assay Time1.75 hr
Sample TypeCell Culture Supernatants, Plasma, Serum.
Sample volume50 μL
Format96-wells plate breakable into 12 x 8 wells strips

Elevate your research experience with our Cytokine/Biomarker Detection Kits, where accuracy, reliability, and ease of use are converging to deliver exceptional results.

存储(Storage)

Keep the unopened kit stored at 2-8 °C. Avoid using the kit beyond its expiration date. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

典型数据-Typical Data Please refer to DS document for the assay protocol.

TARC/CCL17 TYPICAL DATA

For each experiment, a standard curve needs to be set for each microplate, and the specific OD value may vary depending on different laboratories, testers, or equipment. The following example data is for reference only. The sample concentration was calculated based on the results of the standard curve. The minimum detectable concentration of CCL17 is less than 3 pg/mL.

 

验证(Validation)

样本值(Sample Values)

Serum – TARC/CCL17 concentrations were measured in 32 human serum samples, which were collected from healthy human subjects. The measurements of 32 samples are in the range of 1000-4000pg/mL and shown in the figure below.

TARC/CCL17 SAMPLE VALUES

基质效应(Matrix Effect)

3 types of materials were tested to observe if there were matrix effect (interference). If the concentration of hemoglobin (simulated hemolysis) is less than 3500 mg/dL(2%), the concentration of triglyceride (simulated lipid blood) is less than 3 mg/mL, testing results will not be affected.

TARC/CCL17 MATRIX EFFECT

稀释线性(Dilution Linearity)

High concentrations of human TARC/CCL17 serum samples were diluted with 1:2, 1:4, 1:8 and 1:16 ratios for gradient dilution to evaluate the linearity of the assay. In the serum samples, the average detection rate of TARC/CCL17 was 97.89%.

TARC/CCL17 DILUTION LINEARITY

批内差异(Intra-Assay Statistics)

10 replicates of each of 3 samples containing different TARC/CCL17 concentrations were tested in one assay. Acceptable criteria: CV<10%.

TARC/CCL17 INTRA-ASSAY STATISTICS

批间差异(Inter-Assay Statistics)

3 lots of samples containing different concentrations of TARC/CCL17 were tested in the independent assays. Acceptable criteria: CV<15%.

TARC/CCL17 INTER-ASSAY STATISTICS

回收率(Recovery)

TARC/CCL17 was spiked into 3 human serum samples, and then analyzed. The average recovery of TARC/CCL17 for serum samples is 93.93%.

TARC/CCL17 RECOVERY

 

组分(Materials Provided)

IDComponentsSize
CEA029-C01Pre-coated Anti-CCL17 Antibody Microplate1 plate
CEA029-C02Human CCL17 Standard500 μL
CEA029-C03Biotin-Anti-CCL17 Antibody Con. Solution100 μL
CEA029-C04Biotin-Antibody Dilution Buffer8 mL
CEA029-C05Streptavidin-HRP Con. Solution0.5 mL
CEA029-C06Streptavidin-HRP Dilution Buffer15 mL
CEA029-C0720× Washing Buffer50 mL
CEA029-C08Sample Dilution Buffer15 mL ×2
CEA029-C09Substrate Solution12 mL
CEA029-C10Stop Solution6 mL

 
评论(0)
 
ACRO质量管理体系
 
 

前沿进展

Cytokines and chemokines modulate the growth of pituitary adenoma/neuroendocrine tumors: preliminary results of a monocenter prospective pilot study
Chiloiro, Mattogno, Angelini et al
Pituitary (2025) 28 (2), 37
Abstract: Cytokine and chemokines have been recognized to be involved in the progression and prognosis of pituitary adenoma/neuroendocrine tumors (PAs/PitNETs), also known as pituitary adenomas. We aim to investigate the expression of cytokine and chemokine in PAs/PitNETs, and their association with PAs/PitNETs clinical and biological behavior.A prospective and monocenter study was performed on 16 patients diagnosed for PAs/PitNETs. Cytokine and chemokine were detected on freshly collected PAs/PitNETs samples. Tumor infiltering immune cells were investigated on formally fixed and paraffin-embedded PAs/PitNETs samples. Clinical, biochemical, molecular and morphological data were collected from patients' medical records.Out of 72 patients with PAs/PitNETs that underwent surgical removal at the Neurosurgery Division of our Institution between January and June 2023, sixteen patients were enrolled in the study. Out of 42 cytokines and chemokines that we investigated, we found that the expressions of the growth-regulated oncogene (GRO)/CXCL1, thymus- and activation-regulated chemokine (TARC)/CCL17 and epidermal growth factor (EGF) were higher in invasive tumors than in not-invasive ones (respectively p = 0.01, p = 0.002 and p = 0.002). The EGF expression was higher in tumors with a MIB1 > 3% than in those with MIB1 < 3% (p = 0.014). A positive correlation was detected between the expressions of EGF and CXCL1 (p = 0.003, r: 0.7), EGF and GRO-a (p = 0.01, r:0.61), and the number of tumors infiltering CD68 + macrophages and the expression of CCL2 (p = 0.008, r = 0.695).Our preliminary results support that in PAs/PitNETs, the cytokines and chemokines generate an immune network, that may contribute to regulating the cell proliferation and pattern of growth.© 2025. The Author(s).
Thymus and activation-regulated chemokine (CCL17) as a clinical biomarker in atopic dermatitis: significance and limitations in the new treatment era
Kataoka
Front Allergy (2024) 5, 1473902
Abstract: Thymus and activation-regulated chemokine (TARC; CCL17) is a T-helper-2 chemokine that reflects atopic dermatitis (AD) disease activity. Since 2008, serum TARC levels have been commercially measured in Japan, and clinical experience has shown the usefulness of TARC. The fallacy that eczema is always visible often hinders successful treatment, when there is subclinical inflammation which is inferable from the TARC level. AD treatment has entered a new era with higher therapeutic efficacy. TARC has a different meaning than it did previously, and its significance and limitations are discussed. First, a more appropriate topical therapy monitoring TARC would be useful in selecting truly necessitated patients for expensive new therapies. Dupilumab quickly lowers serum TARC before clinical improvement, and its normalization is not a criterion for dose reduction. However, in some severe cases, TARC may help determine whether to continue treatment. During treatment with JAK inhibitors, serum TARC levels are often elevated and may be abnormally high, leading to the exacerbation of dermatitis. Prurigo nodularis is divided into two types associated with elevated and normal TARC levels, which may aid in the selection of therapeutic agents. In this new era, TARC remains a useful biomarker for more accurate drug selection and the determination of therapeutic efficacy; Currently, in clinical trials of AD, all outcome measurements depend on the clinical score; however the use of a biomarker, such as TARC, as a secondary outcome measure will clarify the characteristics of each drug and the pathophysiological conditions for which it is expected to be effective.© 2025 Kataoka.
Characteristic TARC/CCL17 expression in the salivary gland of IgG4-related disease: potential diagnostic utility and insights into pathogenesis
Kikuchi, Hatanaka, Kubo et al
Immunol Med (2025)
Abstract: Immunoglobulin G4-related disease (IgG4-RD) is a chronic inflammatory condition of unknown etiology characterized by lymphocytic infiltration, fibrosis, and infiltration of IgG4-positive plasma cells. It affects various organs, including the pancreas and salivary glands. Immunological abnormalities are suspected to play a role in its pathogenesis, and there is an epidemiological link to allergic conditions and type 2 inflammation. This study focused on the expression of thymus and activation-regulated chemokine (TARC)/CCL17, which is involved in the migration of T helper 2 and/or regulatory T cells, in salivary gland tissues of patients with IgG4-RD. We analyzed 60 salivary gland biopsy samples obtained from patients at Sapporo Medical University Hospital between 2015 and 2020. Immunohistochemical analysis revealed TARC/CCL17 positivity in 87.2% of histologically confirmed IgG4-RD cases and negativity in 84.6% of histologically unconfirmed but clinically suspected IgG4-RD cases. There was a significant correlation between histologically confirmed IgG4-RD and TARC/CCL17 expression, suggesting its potential diagnostic utility and possible involvement in the pathogenesis of IgG4-RD.
Showing 1-4 of 261 papers.
Powered by BizGenius
 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定